Cellectricon Receives Swedish Governmental R&D Grant
GOTHENBURG, Sweden, September 20 /PRNewswire/ --
Cellectricon, a leading provider of microfluidic tools for cell-based assays improve and accelerate drug discovery, has received a grant totaling SEK 2.3 million from VINNOVA (The Swedish Governmental Agency for Innovation Systems). The VINNOVA grant was awarded for the development of Cellectricon's next generation microfluidics platform for high-resolution GPCR screening.
"The VINNOVA grant validates the potential of Cellectricon's unique miniaturized cell-based screening systems for drug discovery", says Dr. Mattias Karlsson, Chief Operating Officer at Cellectricon. "The market acceptance of our launched products together with the VINNOVA grant is gratifying and we will continue to focus on providing innovative solutions for our customers."
Cellectricon AB (Gothenburg, Sweden) invents and develops new types of functional cell-based screening devices for applications in drug discovery and basic research. The company utilizes state of the art interfaces to biological systems by employing novel microfabrication technologies and smart engineering solutions. This enables completely new types of assays and devices with superior performance characteristics and robustness. Cellectricon's products are designed to enable substantial increases in productivity at the highest data quality. The company was formed in 2000 based on an extensive and solid patent portfolio within different areas such as high-throughput electrophysiology, microfluidics, microfabrication, and electroporation.
VINNOVA (The Swedish Governmental Agency for Innovation Systems) is a State authority that aims to promote growth and prosperity throughout Sweden. VINNOVAs particular area of responsibility comprises innovations linked to research and development. VINNOVAs tasks are to fund the needs-driven research required by a competitive business and industrial sector and a flourishing society, and to strengthen the networks that are such a necessary part of this work.